Suppr超能文献

人类肠道微生物群的改变与肝硬化及其并发症相关。

Altered profile of human gut microbiome is associated with cirrhosis and its complications.

作者信息

Bajaj Jasmohan S, Heuman Douglas M, Hylemon Phillip B, Sanyal Arun J, White Melanie B, Monteith Pamela, Noble Nicole A, Unser Ariel B, Daita Kalyani, Fisher Andmorgan R, Sikaroodi Masoumeh, Gillevet Patrick M

机构信息

Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA, United States.

Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA, United States.

出版信息

J Hepatol. 2014 May;60(5):940-7. doi: 10.1016/j.jhep.2013.12.019. Epub 2013 Dec 25.

Abstract

BACKGROUND & AIMS: The gut microbiome is altered in cirrhosis; however its evolution with disease progression is only partly understood. We aimed to study changes in the microbiome over cirrhosis severity, its stability over time and its longitudinal alterations with decompensation.

METHODS

Controls and age-matched cirrhotics (compensated/decompensated/hospitalized) were included. Their stool microbiota was quantified using multi-tagged pyrosequencing. The ratio of autochthonous to non-autochthonous taxa was calculated as the cirrhosis dysbiosis ratio (CDR); a low number indicating dysbiosis. Firstly, the microbiome was compared between controls and cirrhotic sub-groups. Secondly, for stability assessment, stool collected twice within 6months in compensated outpatients was analyzed. Thirdly, changes after decompensation were assessed using (a) longitudinal comparison in patients before/after hepatic encephalopathy development (HE), (b) longitudinal cohort of hospitalized infected cirrhotics MELD-matched to uninfected cirrhotics followed for 30days.

RESULTS

244 subjects [219 cirrhotics (121 compensated outpatients, 54 decompensated outpatients, 44 inpatients) and 25 age-matched controls] were included. CDR was highest in controls (2.05) followed by compensated (0.89), decompensated (0.66), and inpatients (0.32, p<0.0001) and negatively correlated with endotoxin. Microbiota and CDR remained unchanged in stable outpatient cirrhotics (0.91 vs. 0.86, p=0.45). In patients studied before/after HE development, dysbiosis occurred post-HE (CDR: 1.2 to 0.42, p=0.03). In the longitudinal matched-cohort, microbiota were significantly different between infected/uninfected cirrhotics at baseline and a low CDR was associated with death and organ failures within 30days.

CONCLUSIONS

Progressive changes in the gut microbiome accompany cirrhosis and become more severe in the setting of decompensation. The cirrhosis dysbiosis ratio may be a useful quantitative index to describe microbiome alterations accompanying cirrhosis progression.

摘要

背景与目的

肝硬化患者的肠道微生物群会发生改变;然而,人们对其随疾病进展的演变情况仅了解一部分。我们旨在研究微生物群在肝硬化严重程度方面的变化、其随时间的稳定性以及失代偿时的纵向改变。

方法

纳入对照组以及年龄匹配的肝硬化患者(代偿期/失代偿期/住院患者)。使用多标签焦磷酸测序法定量分析他们的粪便微生物群。计算本地菌群与非本地菌群的比例作为肝硬化失调率(CDR);该数值较低表明存在失调。首先,比较对照组与肝硬化亚组之间的微生物群。其次,为进行稳定性评估,分析代偿期门诊患者在6个月内两次采集的粪便。第三,使用以下方法评估失代偿后的变化:(a)对肝性脑病(HE)发生前后的患者进行纵向比较,(b)对住院的感染性肝硬化患者与未感染的肝硬化患者进行MELD匹配的纵向队列研究,随访30天。

结果

纳入244名受试者[219名肝硬化患者(121名代偿期门诊患者、54名失代偿期门诊患者、44名住院患者)和25名年龄匹配的对照组]。CDR在对照组中最高(2.05),其次是代偿期患者(0.89)、失代偿期患者(0.66)和住院患者(0.32,p<0.0001),且与内毒素呈负相关。稳定的门诊肝硬化患者的微生物群和CDR保持不变(0.91对0.86,p=0.45)。在对HE发生前后进行研究的患者中,失调发生在HE之后(CDR:1.2至0.42,p=0.03)。在纵向匹配队列中,感染/未感染的肝硬化患者在基线时微生物群存在显著差异,低CDR与30天内的死亡和器官衰竭相关。

结论

肠道微生物群的渐进性变化伴随肝硬化发生,并在失代偿情况下变得更加严重。肝硬化失调率可能是描述肝硬化进展过程中微生物群改变的有用定量指标。

相似文献

1
Altered profile of human gut microbiome is associated with cirrhosis and its complications.
J Hepatol. 2014 May;60(5):940-7. doi: 10.1016/j.jhep.2013.12.019. Epub 2013 Dec 25.
2
Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy.
Hepatology. 2015 Oct;62(4):1260-71. doi: 10.1002/hep.27819. Epub 2015 May 6.
3
Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.
Gut. 2021 Jun;70(6):1162-1173. doi: 10.1136/gutjnl-2020-322470. Epub 2020 Sep 30.
4
Fungal dysbiosis in cirrhosis.
Gut. 2018 Jun;67(6):1146-1154. doi: 10.1136/gutjnl-2016-313170. Epub 2017 Jun 3.
5
Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis.
Aliment Pharmacol Ther. 2017 Jan;45(2):319-331. doi: 10.1111/apt.13858. Epub 2016 Nov 20.
6
Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation.
Am J Physiol Gastrointest Liver Physiol. 2012 Sep 15;303(6):G675-85. doi: 10.1152/ajpgi.00152.2012. Epub 2012 Jul 19.
7
Linkage of gut microbiome with cognition in hepatic encephalopathy.
Am J Physiol Gastrointest Liver Physiol. 2012 Jan 1;302(1):G168-75. doi: 10.1152/ajpgi.00190.2011. Epub 2011 Sep 22.
8
Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis.
Clin Gastroenterol Hepatol. 2019 Mar;17(4):756-765.e3. doi: 10.1016/j.cgh.2018.07.022. Epub 2018 Jul 20.
9
Gut microbial RNA and DNA analysis predicts hospitalizations in cirrhosis.
JCI Insight. 2018 Mar 8;3(5):98019. doi: 10.1172/jci.insight.98019.
10
Clinical impact of microbiome in patients with decompensated cirrhosis.
World J Gastroenterol. 2018 Sep 14;24(34):3813-3820. doi: 10.3748/wjg.v24.i34.3813.

引用本文的文献

2
Mucosal microbiota signatures reveal diagnostic insights in chronic liver disease.
BMC Gastroenterol. 2025 Aug 21;25(1):607. doi: 10.1186/s12876-025-04204-3.
3
The role of bacterial outer membrane vesicles in inflammatory response of acute-on-chronic liver failure.
Front Microbiol. 2025 Jul 4;16:1608137. doi: 10.3389/fmicb.2025.1608137. eCollection 2025.
4
Enhancement of oxaliplatin efficacy and amelioration of intestinal epithelial damage by GG through modulation of gut microbiota.
Front Microbiol. 2025 Jun 30;16:1565880. doi: 10.3389/fmicb.2025.1565880. eCollection 2025.
6
Analysis of gut and circulating microbiota characteristics in patients with liver cirrhosis and portal vein thrombosis.
Front Microbiol. 2025 Jun 19;16:1597145. doi: 10.3389/fmicb.2025.1597145. eCollection 2025.
8
Fecal Butyrate and Deoxycholic Acid Concentrations Correlate With Mortality in Patients With Liver Disease.
Gastro Hep Adv. 2025 May 9;4(8):100695. doi: 10.1016/j.gastha.2025.100695. eCollection 2025.

本文引用的文献

1
Large-scale survey of gut microbiota associated with MHE Via 16S rRNA-based pyrosequencing.
Am J Gastroenterol. 2013 Oct;108(10):1601-11. doi: 10.1038/ajg.2013.221. Epub 2013 Jul 23.
2
Analyses of the stability and core taxonomic memberships of the human microbiome.
PLoS One. 2013 May 6;8(5):e63139. doi: 10.1371/journal.pone.0063139. Print 2013.
3
Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.
PLoS One. 2013;8(4):e60042. doi: 10.1371/journal.pone.0060042. Epub 2013 Apr 2.
4
Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.
Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9. doi: 10.1053/j.gastro.2013.02.042. Epub 2013 Mar 6.
5
Modulation of the fecal bile acid profile by gut microbiota in cirrhosis.
J Hepatol. 2013 May;58(5):949-55. doi: 10.1016/j.jhep.2013.01.003. Epub 2013 Jan 16.
6
Gut microbiota disturbance during antibiotic therapy: a multi-omic approach.
Gut. 2013 Nov;62(11):1591-601. doi: 10.1136/gutjnl-2012-303184. Epub 2012 Dec 12.
7
The gut microbiota and the liver. Pathophysiological and clinical implications.
J Hepatol. 2013 May;58(5):1020-7. doi: 10.1016/j.jhep.2012.11.023. Epub 2012 Nov 23.
8
The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease.
Front Physiol. 2012 Oct 11;3:402. doi: 10.3389/fphys.2012.00402. eCollection 2012.
10
Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation.
Am J Physiol Gastrointest Liver Physiol. 2012 Sep 15;303(6):G675-85. doi: 10.1152/ajpgi.00152.2012. Epub 2012 Jul 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验